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 INTRODUCTION 
 Artemisinin-based combination therapies (ACTs) are now 
the recommended first-line treatment of falciparum malaria 
globally, because they rapidly decrease parasitemia, hasten 
recovery, and reduce chances of development of drug resis-
tance. 1, 2 Of the available ACTs, artesunate-amodiaquine 
(AA) and artemether-lumefantrine (AL) seem to be the most 
widely used. 3– 7 Although there are many formulations of AA, 
including coformulated (AAcf) or fixed-dose and copackaged 
(AAcp), it is generally assumed that AAcf may improve com-
pliance and treatment outcomes because of a simple dosing 
regimen and fewer tablets compared with AAcp. In addition, 
fixed combination prevents the use of monotherapy, which can 
contribute to antimalarial drug resistance, because only the 
artemisinin component of the coblistered packages is often 
taken. A recent study in five African countries has shown that 
fixed-dose AA is as efficacious as AL in children. 8 However, 
there are few or no recent studies comparing fixed-dose and 
copackaged AA with AL in malarious African children. It is, 
therefore, necessary to evaluate whether AAcf or AAcp is bio-
logically and therapeutically equivalent in malarious children 
in endemic areas, because cost and effectiveness are issues 
that may militate against reduction of morbidity and mortal-
ity in these areas. In addition,  in vitro studies have shown that 
both amodiaquine and AL are associated with selection of 
 Plasmodium falciparum multidrug resistance gene 1 (Pfmdr 
gene 1), which is associated with recrudescence to antimalarial 
drugs, in children after treatment. 9, 10 
 In this study, we report the tolerability, antimalarial treatment 
efficacy, and effects on malaria-associated anemia (MAA) of 
AAcp, AAcf, and AL in children ≤ 12 years of age with acute 
symptomatic, uncomplicated  P. falciparum malaria. 
 MATERIAL AND METHODS 
 Study area.  The study was carried out in Ibadan in 
southwestern Nigeria from July 2009 to May 2010. In this 
area of hyperendemic malaria, transmission occurs all year 
round but is more intense during the rainy season from April 
to October. 11 The prevalence of AL, AA, and amodiaquine 
resistance in the area has been reported to be < 2%, 2%, and 
4%, respectively. 7, 9, 12 
 Patients, treatment, and follow-up.  Patients were eligible 
to participate in the study if they were ≤ 12 years of age, had 
symptoms compatible with acute uncomplicated malaria such 
as anorexia, vomiting, or abdominal discomfort with or without 
diarrhea, had  P. falciparum parasitemia > 2,000 asexual forms/
μL, had a body (axillary) temperature > 37.4°C or history of 
fever in the 24–48 hours preceding presentation, had absence 
of other concomitant illness, had no history of antimalarial drug 
use in the 2 weeks preceding presentation, and had written 
informed consent given by parents or guardians. Patients 
with severe malaria, 13 severe malnutrition, serious underlying 
diseases (renal, cardiac, or hepatic), and known allergy to 
study drugs were excluded from the study. The study protocol 
was reviewed and approved by the Ethics Committee of the 
Ministry of Health, Ibadan. The disease history, taken by the 
attending physician, was recorded by asking patients or their 
parents or guardians when the present symptomatic period 
started, and this was followed by a full physical examination 
by the same physician. 
 Enrolled patients were randomly assigned to receive AL, 
AAcf, or AAcp in a ratio of 2:3:3. AL (Coartem; Novartis, 
Basel, Switzerland) was given according to body weight: 
patients weighing 5–14 kg received one tablet, those weigh-
ing 14–24 kg received two tablets, those weighing 25–34 kg 
received three tablets, and those weighing more than 34 kg 
received four tablets at presentation (0 hours), 8 hours later, 
and 24, 36, 48, and 60 hours after the first dose. Each tablet 
of AL contains 20 mg artemether and 120 mg lumefantrine. 
AAcf (Coarsucam; Sanofi Aventis, Casablanca, Morocco) was 
given as follows: children weighing ≥ 9 to < 18 kg or aged 1–5 
years received 0.5 tablets, children weighing ≥ 18–36 kg or aged 
6–13 years received one tablet, and children weighing ≥ 36 kg 
or aged ≥ 14 years received two tablets. Each tablet of AAcf 
contains 270 mg amodiaquine base and 100 mg artesunate 
coformulated in a bilayer. AAcp (Dart; Swiss Pharma, Lagos, 
Nigeria) was given according to age or body weight as follow: 
1–5 years or 5–15 kg received one tablet each of amodiaquine 
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and artesunate, 6–10 years or 16–24 kg received two tablets 
each of amodiaquine and artesunate, and 11–15 years or 25–34 
kg received three tablets each of amodiaquine and artesunate. 
Each tablet of amodiaquine contains 153 mg base, and each 
tablet of artesunate contains 50 mg in the copacked unit. 
 All drugs were given orally, and all patients waited for at 
least 3 hours to ensure that the drugs were not vomited. If they 
were, the patient was excluded from the study. If necessary, 
patients were provided with antipyretics (paracetamol tablets, 
10–15 mg/kg every 8 hours for 24 hours). The randomization 
was computer generated, and treatment codes were sealed in 
individual envelopes. Patient evaluation at enrolment and fol-
low-up after drug administration was performed by another 
physician blinded to the drug treatment. The study nurse 
obtained thick and thin blood films from each child as soon as 
they came to the clinic. The slides were carefully labeled with 
the patients’ codes and were air-dried before staining. 
 Follow-up with clinical and parasitological evaluation was 
carried out at 0, 1, 2, 4, 8, 16, and 24 hours after treatment daily 
on days 2–7, 14, 21, 28, 35, and 42. These consisted of enquiry 
about the patient’s well-being, presence or absence of initial 
presenting symptoms, and presence of additional symptoms, 
measurement of body temperature, heart rate, and respira-
tory rate, and taking a blood smear for the quantification of 
parasitemia. 
 Side effects were defined as symptoms and signs that first 
occurred or became worse after treatment was started. Any 
new events occurring during treatment were also considered 
as side effects. 
 Thick and thin blood films prepared from a finger prick were 
stained with Geimsa and examined by light microscopy under 
an oil-immersion objective at 1,000× magnification by two 
independent assessors who did not know the drug treatment 
of the patient. A senior member of the study team reviewed 
the slides if there was any disagreement between the micros-
copists. In addition, the slides of every third child enrolled in 
the study were reviewed by this senior member. Parasitemia 
(asexual or sexual) in thick films was estimated by counting 
asexual or sexual parasites relative to 1,000 leukocytes or 500 
asexual or sexual forms, whichever occurred first. From this 
figure, the parasite density was calculated assuming a leuko-
cyte count of 6,000/1 μL blood. 
 Capillary blood collected before and during follow-up 
was used to measure packed cell volume (PCV) or hemat-
ocrit. Hematocrits were measured using a microhematocrit 
tube and microcentrifuge (Hawksley, Lancing, UK). Routine 
hematocrit was done on days 0–7, 14, 21, 28, 35, and 42. Drug-
attributable fall in hematocrit (DAFH) during treatment was 
defined as the difference between the patient’s hematocrit 
on day 0 and day 3 after starting treatment. 14 Anemia reso-
lution time (AnRT) was defined as the time for hematocrit 
value to return to 30% in those that were anemic at presenta-
tion. Area under the curve of deficit in hematocrit (AUC def ) 
was calculated as previously described. 15 Briefly, in all ane-
mic patients (PCV < 30%), hematocrit values below 30% 
(the lower threshold of normal) at enrollment and follow-up 
were subtracted from 30% at each time of measurement until 
hematocrit rose to 30%, and the resulting values were plotted 
against time. The deficit in hematocrit when anemia resolved 
was, therefore, zero in all patients. The AUCs of deficit in 
hematocrit (from 30%) versus time were obtained by the trap-
ezoidal rule using the computer program Turbo Ken (designed 
by Clinical Pharmacology Group, University of Southampton, 
Southampton, UK ). If there was no resolution of anemia dur-
ing follow-up, AUC was calculated until 1,008 hours (day 42). 
AUC was also obtained manually by calculating the average 
hematocrit values between two consecutive time measure-
ments, multiplying this number by the time interval between 
the measurements, and summing up all the values in a manner 
similar to that for the numeric estimation of area under a drug 
concentration–time curve. 16 Both measurements by digital 
computer and manual methods gave the same values. The unit 
of quantification would be %h if hematocrit values were used 
or g.h/dL if hemoglobin values were used. Hematocrit values 
may be converted to hemoglobin values by dividing by three. 
 Blood was spotted on filter papers on days 0, 3, 7, 14, 21, 
28, 35, and 42 and at the time of treatment failure for parasite 
genotyping. Paired primary and post-treatment parasites were 
analyzed using parasite loci that exhibit repeated numbers of 
polymorphisms to distinguish true treatment failures from 
new infections. Briefly, block 2 of merozoite surface protein-1 
(MSP-1), block 3 of MSP-2, and region II of glutamine-rich 
protein (GLURP) were amplified by two rounds of poly-
merase chain reaction (PCR) using primers and amplification 
conditions described previously. 10 Ten microliters of nested 
PCR products were resolved by electrophoresis on a 2% aga-
rose gel and sized against a 100-bp molecular weight marker 
(New England Biolabs, Beverly, MA). The banding pattern of 
the post-treatment parasites was compared with matched pri-
mary parasites in each of the patients who had parasitemia 
after treatment with either AL or AA. Post-treatment and pri-
mary infection parasites showing identical bands were consid-
ered true treatment failure, whereas non-identity in banding 
patterns was considered newly acquired infection. 
 Response to drug treatment was assessed using World 
Health Organization (WHO) 1973 criteria 17 as follows: S = 
sensitive, clearance of parasitemia without recurrence; RI 
(mild resistance) = parasitemia disappears but reappears 
within 7–14 days; RII (moderate resistance) = decrease of 
parasitemia but no complete clearance from peripheral blood; 
RIII (severe resistance) = no pronounced decrease or increase 
in parasitemia at 48 hours after treatment. In those with sensi-
tive or mild resistance, parasite clearance time was defined as 
the time elapsing between drug administration and absence 
of detectable parasitemia for at least 48 hours. Times taken to 
clear 50% and 90% parasitemia were calculated from the plot 
of decline in parasitemia versus time. Fever clearance time was 
defined as the time from drug administration until the body 
temperature fell to or below 37.4°C and remained so for 48 
hours. Response to drug treatment was also classified accord-
ing to a modified version of the WHO 14-day  in vivo clinical 
classification system 18 ; because all patients were not febrile at 
enrolment, a temperature < 37.5°C was not an exclusion crite-
rion for enrolment. The modification also involved a follow-
up for 42 days in this area of intense transmission. The clinical 
classification system consisted of the following categories 
of response: adequate clinical and parasitological response 
(ACPR), late parasitological failure (LPF), late clinical failure 
(LCF), and early treatment failure (ETF). 
 Cure rates were defined as the percentages of patients whose 
asexual parasitemia cleared from peripheral blood and who 
were free of patent asexual parasitemia on days 14, 21, 28, 35, 
and 42 of follow-up. The cure rates on days 21–42 were adjusted 
on the basis of the PCR genotyping results of paired samples 
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for patients with recurrent parasitemia after day 14 of com-
mencing treatment. 
 Retreatment of drug treatment failures.  All patients failing 
treatment (within 35 days) with AL, AAcf, or AAcp were 
retreated with these drug combinations and were followed 
for 42 days. Patients were retreated whenever they became 
symptomatic (usually between 23 and 42 days after initial 
enrolment). Patients with profound clinical (hyperpyrexia 
or oral fluid intolerance) and parasitological deterioration 
(> 20% increase in baseline parasitemia) during follow-up 
were treated with parenteral quinine and were regarded as 
treatment failures. 
 Data analysis.  Sample size was calculated so that the 
study would be able to detect a 14% absolute difference in 
parasitologic failure rate between AL on one hand and AAcf 
and AAcp groups on the other hand with 80% power and a 
5% significance level. The expected treatment success rates 
were 99% for AL and 85% for AAcf and AAcp on days 
28–42. At a randomization ratio of 1:1.5:1.5 for AL, AAcf, 
and AAcp, respectively, the minimum sample size in each 
treatment arm was 63, 95, and 95, respectively, for AL, AAcf, 
and AAcp. Data were analyzed using version 6 of the Epi-
Info software 19 and the statistical program SPSS for Windows 
version 10.01. 20 Variables considered in the analysis were 
related to the densities of  P. falciparum gametocytes and 
trophozoites. Proportions were compared by calculating χ 2 
with Yates’ correction or using Fisher exact tests. Normally 
distributed, continuous data were compared by Student  t test 
and analysis of variance (ANOVA). Data not conforming to 
a normal distribution were compared by the Mann–Whitney 
 U tests, the Kruskal–Wallis tests, or the Wilcoxon ranked 
sum tests. All tests of significance were two-tailed.  P values ≤ 
0.05 were taken to indicate significant differences. Data were 
double-entered serially using the patients’ codes and were 
only analyzed at the end of the study. 
 RESULTS 
 Patient characteristics.  Between July 2009 and May 2010, 
285 children were recruited: 81 in the AL group, 100 in the 
AAcf group, and 104 in the AAcp group. There were 67 
children less than 5 years old: 20 (24.6%) in the AL group, 20 
(20%) in the AAcf group, and 27 (26%) in the AAcp group. 
 Table 1 shows the characteristics of children enrolled in the 
study. The characteristics of the children in the three groups 
were similar at enrolment. Overall, 267 children completed 
at least 28 days of follow-up ( Figure 1 ). Of the remaining 18 
children, 12 children completed 21 days, 5 children completed 
14 days, and 1 child completed 7 days of follow-up; 265 children 
completed 42 days of follow-up. Virtually all children who did 
not complete 42 days of follow-up relocated from the area of 
study or had recurrence of parasitemia on or before day 42. 
 Fever and parasite clearance.  Two hundred thirty-two 
children were febrile at enrolment: 61 in the AL group, 82 in 
the AAcf group, and 89 in the AAcp group. By day 1, fever 
cleared in 213 (92%) of the children: 53, 77, and 83 children in 
AL, AAcf, and AAcp groups, respectively. These proportions 
were similar in the three groups (χ 2 = 2.69, degree of freedom 
[df] = 2,  P = 0.26). By day 2, fever had cleared in all children. 
Overall, fever clearance time was similar in the three groups 
( Table 2 ). Similarly, parasitemia cleared in 262 (92%) of the 
children by day 1: 73, 92, and 97 children in AL, AAcf, and 
AAcp groups, respectively. Overall parasite clearance times in 
the three treatment arms were similar: 21.4 ± 9.1, 20.9 ± 9.3, and 
19.1 ± 8.3 hours in AL, AAcf, and AAcp groups, respectively 
( P = 0.17) ( Table 2 ). Times to clear 50% and 90% parasitemia 
were also similar. Response to the three treatment regimens 
was not related to age. Fever clearance was similar in children 
< 5 and ≥ 5 years (1.1 ± 0.3 versus 1.1 ± 0.3 days, respectively; 
 P = 0.73). Similarly, parasite clearance was similar in children 
< 5 and ≥ 5 years (18.1 ± 6.6 versus 20.3 ± 9.0 hours, respectively; 
 P = 0.28). Overall, 1 of 67 and 4 of 196 children < 5 and 
≥ 5 years old, respectively, had reappearance of parasitemia by 
day 42 (χ 2 = 0.055,  P = 0.82). All 284 children treated with AL, 
AAcf, and AAcp had ACP up to day 14. 
 Gametocyte carriage.  At enrolment, gametocytes were 
detected in the peripheral blood of eight patients: two in 
the AL group, four in the AAcf group, and two in the AAcp 
group. One week after treatment, gametocytes were found in 
peripheral blood of five children: one in the AL group, two 
in the AAcf group, and two in the AAcp group. These five 
patients did not have gametocytes at enrolment. 
 Rate of reappearance of parasitemia.  Five of two hundred 
sixty-eight children who completed at least 28 days follow-up 
had reappearance of parasitemia (three in the AL group, one 
 Table 1 
 Demographic and clinical characteristics of patients and immediate 
therapeutic responses 
AL AAcf AAcp
No. of patients 81 100 104
Male/female 43/37 55/45 57/45
Age (years)
 Mean (SD) 7.2 (3.0) 7.4 (2.8) 7.2 (3.4)
 Range 1.17–12 0.67–12 1.5–12
No. < 5 years 20 20 27
Weight (kg)
 Mean (SD) 19.9 (7.4) 19.6 (6.3) 19.5 (7.1)
 Range 7–59 6–39 7–42
Height (cm)
 Mean (SD) 115.2 (17.3) 116.7 (17.9) 115.3 (19.8)
 Range 70–150 65–157 62–151
Hematocrit (%)
 Mean (SD) 32.6 (4.4) 31.7 (4.4) 32.3(4.5)
 Range 22–40 17–40 20–44
Temperature (°C)
 Mean (SD) 38.4 (1.2) 38.4 (1.1) 38.4 (1.2)
 Range 36–40.6 36–41.1 35.9–40.5
Duration of illness (days)
 Mean (SD) 2.8 (1.2) 2.7 (1.4) 2.7 (1.3)
 Range 1–7 1–7 1–7
Pulse rate per minute
 Mean (SD) 123.2 (20.7) 119.3 (20.1) 122 (22.9)
 Range 62–180 72–184 68–192
Respiration rate per minute
 Mean (SD) 30.4 (6.8) 30.6 (7.3) 30.6 (8.0)
 Range 20–60 20–56 22–80
GMPD per 
microliter blood 71,794 56,102 64,145
 Range 2,024–459,000 2,504–346,153 3,749–1,096,636
 > 250,000 5 4 4
GMGD per 
microliter blood 88 18 127
 Range 72–108 6–54 36–450
  N 2 4 2
Hepatomegaly 25 21 24
Splenomegaly 29 23 25
Hepatosplenomegaly 6 9 7
 AL = artemether-lumefantrine; AAcf = artesunate-amodiaaquine coformulated; AAcp = 
artesunate-amodiaquine copackaged ; SD = standard deviation; GMGD = geometric mean 
gametocyte density; GMPD = geometric mean parasite density. 
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in the AAcf group, and one in the AAcp group) after initial 
clearance of parasitemia between days 21 and 42. There was 
no significant difference in the proportions of patients with 
reappearance of parasitemia in the three treatment arms 
(χ 2 = 2.5,  P = 0.29) ( Table 2 ). Kaplan–Meier survival analysis 
showed that there was no significant difference in the rate of 
reappearance of parasitemia during follow-up between the 
three treatment arms (log rank statistic = −1.83,  P = 0.18). 
 PCR findings.  All five patients who were parasitemic during 
follow-up had their samples analyzed at enrolment and post-
treatment. Parasite genotypes in the pre- and post-treatment 
samples were non-identical in one patient treated with AAcf 
and were considered as newly acquired infections. In three 
patients treated with AL and one patient treated with AAcp, 
parasite genotypes in the pre- and post-treatment samples 
were identical and considered as recrudescence. 
 Adverse events.  Overall, 66 children (19 in the AL group, 
24 in the AAcf group, and 23 in the AAcp group) reported 
at least one adverse event within the first week of starting 
treatment from a list of solicited adverse events: anorexia, 
vomiting, headache, cough, abdominal pain, diarrhea, fever, 
rash, itching, excessive salivation, puffy face, and herpetic 
eruptions. The most frequent (> 20%) solicited adverse event 
was cough ( Table 3 ). There was no child reporting more than 
three adverse events. All adverse events were reversible and 
did not require hospitalization. 
 DAFH and resolution of anemia after treatment.  Hematocrit 
data were available in 270 children: 77, 96, and 97 in AL, 
AAcf, and AAcp groups, respectively. Hematocrit values were 
available in 260 patients both on day 0 and 3; these were used 
for the assessment of DAFH. Of these children, 45, 56, and 
57 had a fall in hematocrit on day 3 in AL, AAcf, and AAcp 
groups, respectively. The proportions of children with a fall 
in hematocrit on day 3 were similar in all treatment groups 
(χ 2 = 0.04,  P = 0.98). DAFH values were also similar in the 
three treatment groups (4.4 ± 3.3%, 95% confidence interval 
[CI] = 2–4.4%; 4.0 ± 2.4%, 95% CI = 3.0–4.9%; 3.4 ± 2.0%, 95% 
CI = 2.7–4.9%, respectively;  P = 0.17) ( Figure 2 ). In general, 
the rates of rise in hematocrit in the three treatment groups 
were also similar ( Figure 2 ) such that, by day 28, there were no 
more increases in hematocrit values in all treatment groups. 
Overall, 66 children were considered anemic (PCV < 30%) at 
enrolment: 17 in the AL group, 28 in the AAcf group, and 21 
in the AAcp group.  Table 4 shows the rates of resolution of 
anemia after treatment in the 66 children in whom complete 
data were available from days 0 to 42. These rates were similar. 
Anemia resolution times were also similar: 11.4 ± 6.1, 11.0 ± 
4.5, and 13.0 ± 4.1 days in the AL, AAcf, and AAcp groups, 
respectively ( P = 0.42) ( Table 4 ). 
 Comparison of AUC of deficit in hematocrit.  Figure 3A 
shows the distribution of individual AUC def in the three 
treatment groups. Mean AUC def was similar in the three 
 Figure 1.  Trial profile for the study. 
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groups (35.7%.d in the AL group, 24.8%.d in the AAcf group, 
and 40%.d in the AAcp group;  P = 0.27) ( Figure 3B ). The 
proportion of children with AUC def > 30%.d was also similar 
(6 of 16, 10 of 28, and 10 of 19 in the AL, AAcf, and AAcp 
groups, respectively;  P = 0.48). 
 DISCUSSION 
 Of the ACTs, AL and AA are the most frequently used 
in Africa. 3– 7, 14 However, very few studies have evaluated the 
safety, tolerability, effects on gametocyte carriage, and recov-
ery from malaria-associated anemia of both fixed-dose and 
copackaged combination of AA and compared these with AL 
in malarious children. 14 We documented the tolerability, safety, 
and efficacy of AL, AAcf, and AAcp in the treatment of uncom-
plicated  P. falciparum malaria, and the study was based on a 
42-day follow-up. In the children studied, parasite clearance 
was similar in all treatment regimens. In addition, clearance 
rates were similar in younger (< 5 years) and older children, 
suggesting that clearance of parasites in these children is inde-
pendent of immunity. 21 It is particularly noteworthy that clear-
ance was similar whether it was copackaged or coformulated; 
fever clearance was similar in all treatment groups. 
 Amodiquine has antipyretic propertyies. 22 It is, therefore, 
surprising that, in patients treated with AL where the lume-
fantrine component has little or no antipyretic property, fever 
clearance was similar to that of the children treated with AA. 
This would suggest that, in this cohort of children, fever clear-
ance paralleled parasite clearance. This finding is in contrast 
to a finding from the same area where the amodiaquine com-
ponent of amodiaquine sulfalene-pyrimethamine produced a 
similar fever clearance with AL, despite a slower clearance of 
parasitemia. 12 Prompt fever and parasite clearance times by 
both AL and the formulations of AA are in agreement with 
findings from Africa and elsewhere. 5, 6, 8, 12, 23 
 Gametocyte carriage at enrolment in the cohort of children 
evaluated (3%) was lower than in previous studies from the 
same area during the use of monotherapies (10–12%). 24 ACTs 
have been used consistently in children from the study commu-
nity in the last 5 years and may have been responsible for the 
relatively low gametocyte carriage compared with the pre-ACT 
use period. The low gametocyte carriage rate made it impos-
sible to accurately assess the effects of ACTs on gametocyte 
carriage, emergence, and clearance as was previously reported 
in a recent study from this endemic endemic. 25 However, it is 
possible that gametocyte carriage rates are underestimates, 
because submicroscopic gametocytemia is common in this and 
other endemic areas. 9, 26, 27 This would explain the non-reduc-
tion in transmission intensity, which was evidenced by the high 
parasite rate of 43% in the present study ( Figure 1 ) despite the 
low gametocyte carriage after consistent ACT. However, in the 
few patients that carried gametocytes at enrolment, gameto-
cytemia cleared within 3 days. 
 Recovery from malaria-associated anemia was similar in the 
three treatment groups and took approximately 1.5–2 weeks in 
 Table 2 
 Therapeutic responses to artemether-lumefantrine (AL), artesunate-
amodiaquine coformulated (AAcf), or artesunate-amodiaquine 
copackaged (AAcp) 
AL AAcf AAcp  P value
No. of patients 81 100 104 –
Fever clearance time (days)  N = 61  N = 82  N = 89
 Mean ± SD 1.1 ± 0.3 1.0 ± 0.2 1.0 ± 0.3 0.26
 Range 1–2 1–2 1–2
 95% CI 1.04–1.2 1.01–1.1 1.01–1.12
No. of patients with 
parasitemia on day 1
4 6 6 0.35
Time to clear 50% parasitemia (hours)
 Mean ± SD 10.7 ± 4.6 10.4 ± 4.6 9.6 ± 4.2 0.18
 Range 2–24 2–24 2–24
 95% CI 9.7–11.7 9.5–11.4 8.8–10.4
Time to clear 90% parasitemia (hours)
 Mean ± SD 19.3 ± 8.2 18.8 ± 8.3 17.2 ± 7.5 0.18
 Range 3.6–43.2 3.6–43.2 3.6–43.2
 95% CI 17.5–21.1 17.1–20.5 15.6–18.7
Parasite clearance time (hours)
 Mean ± SD 21.4 ± 9.1 20.9 ± 9.3 19.1 ± 8.3 0.18
 Range 4–48 4–48 4–48
 95% CI 19.4–23.4 19.0–22.7 17.5–20.8
Day and responses (S/RI/RII)
 14 81/0/0 100//0 104/0/0 –
 21 81/0/ 100/0/ 104/0/ –
 28 80/1/ 99/1/ 104/0/ 0.55
 35 79/2/ 99/1/ 103/1/ 0.63
 42 78/3/ 99/1/ 103/1/ 0.29
ACPR (%) 78 (96.3) 99 (99) 103 (99) 0.29
LPF (%) 3 (3.7) 1 (1) 1 (1)
LCF 0 0 0
ETF 0 0 0
PCR-corrected cure rate (%) 96.3 100 99 0.09
 AL = artemether-lumefantrine; AAcf = artesunate-amodiaaquine coformulated; AAcp = 
artesunate-amodiaquine copackaged; SD = standard deviation. 
 Table 3 
 Adverse events reported within the first week of the study 
AL AAcf AAcp  P value
No. of children 81 100 104 –
Total reporting adverse event 19 24 23 0.95
Cough 9 7 7 0.40
Pruritus 0 3 3 0.26
Vomiting 1 2 2 0.90
Abdominal pain 0 3 7 0.02
Weakness 2 5 4 0.66
Insomnia 0 0 3 0.053
Diarrhea 3 3 2 0.78
Herpes labialis 0 2 1 0.43
Excessive salivation 1 4 1 0.27
Rashes 2 1 2 0.71
Puffy face 1 0 1 0.55
Dizziness 0 1 1 0.66
Headache 0 1 0 0.41
 AL = artemether-lumefantrine; AAcf = artesunate-amodiaaquine coformulated; AAcp = 
artesunate-amodiaquine copackaged. 
 Figure 2.  Changes in hematocrit before, during, and after treat-
ment with AL (solid line), AAcf (broken line), or AAcp (dotted line) 
in malarious children. 
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patients who were anemic on presentation. In addition, recov-
ery from the total malaria-attributable fall in hematocrit 28, 29 
(defined as the time interval between hematocrit levels on 
days 3 and 28 in this study, a time when no further increases 
in hematocrit levels were seen in the absence of malaria infec-
tion) seems to be shorter than that reported in the same area 
when monotherapies were used (approximately 5 weeks). 29 
This would suggest that, compared with non-ACTs, ACTs may 
hasten recovery in malaria-associated anemic children from 
this endemic area. 
 Further evaluation of the effects of the three treatments on 
recovery from malaria-associated anemia was also done using 
the area inscribed by plotting the deficit in hematocrit versus 
time. This method seems to be more sensitive than the con-
ventional estimation of anemia recovery time. 15 Using this 
method, we showed that the areas under curve of the deficit 
in hematocrit versus time were similar, suggesting that, in this 
cohort of children, the use of AL or AAcf has no advantage 
over AAcp. This indicates that the artemisinin components 
of these ACTs are the major contributors to the observed 
responses. This should predicted, because artemisinin drugs 
are known to cause lesser degrees of fall in hematocrit, par-
ticularly in patients with heavy parasitemia. 30, 31 
 All three treatments were well-tolerated; adverse drugs reac-
tions reported during the study were indistinguishable from those 
of malaria. No patient treated with AL had pruritus. Because 
lumefantrine is closely related to halofantrine, which has been 
reported to induce chloroquine-like pruritus, 32 it is likely that 
AL-induced pruritus will be encountered as use of AL increases 
in the future. In conclusion, AL, AAcf, and AAcp administered 
over 3 days produced similar clinical and parasitological efficacy 
and similar effects on the recovery from the malaria-associated 
anemia. Use of AL or AAcf has no advantage in terms of effi-
cacy or recovery from  P. falciparum -associated malaria over 
AAcp. These antimalarial combinations offer effective treat-
ment of uncomplicated falciparum malaria in children. 
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 Table 4 
 Resolution of malaria-associated anemia after treatment 
AL AAcf AAcp  P 
No. with PCV < 30% 17 ( N = 81) 28 ( N = 100) 21 ( N = 104) 0.36
Mean PCV (%) and range 23.8% (22–29) 24% (17–29) 22.4% (20–29) 0.35
No. of males (%) 8 (47.5) 18 (64.3) 14 (66.7) 0.41
Age (years)
 Mean ± SD 4.8 ± 2.5 6.6 ± 2.9 5.4 ± 3.8 0.49
 Range 1.17–12 2–10 1.83–12
 No. < 5 years 6 7 8 0.59
Parasite count (per microliter)
 Geometric mean 113,716 73,221 75,458 0.30
 Range 2,024–288,461 16,393–346,156 8,159–1,096,636
No. with gametocytemia at presentation (%) 0 3 0 0.08
No. with PCV < 30 (%) on that specific day
 Day 7 10 ( N = 14) 15 ( N = 27) 14 ( N = 19) 0.38
 Day 14 3 ( N = 12) 2 ( N = 20) 3 ( N = 16) 0.53
 Day 21 2 ( N = 10) 1 ( N = 19) 2 ( N = 17) 0.48
 Day 28 2 ( N = 9) 0 1 ( N = 10) 0.58
 Day 35 2 ( N = 9) 0 1 ( N = 9) 1.0
 Day 42 1 ( N = 9) 0 0 –
Anemia resolution time (day) 11.4 ± 6.1 11.0 ±4.5 13.0 ± 4.1 0.42
DAFH (%) range 4.4 ± 3.3 4.0 ± 2.4 3.4 ± 2.0 0.17 
1–10 1–10 1–9
 N 44 56 57
 AL = artemether-lumefantrine; AAcf = artesunate-amodiaaquine coformulated; AAcp = artesunate-amodiaquine copackaged; SD = standard deviation; DAFH = drug-attributable fall in 
hematocrit. 
 Figure 3.  Individual ( A ) and group mean ( B ) AUCs of deficit 
in hematocrit in patients treated with AL (solid line), AAcf (broken 
line), and AAcp (dotted line). In  A , horizontal bars indicate group 
mean values. 
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